Alexandria, VA – July 23, 2025 — Pinco Biotherapeutics announced its participation in the July 2025 Seed2Table Life Sciences Pitch Event, a curated forum connecting early-stage biotech companies with investors, operators, and ecosystem leaders across the Washington, DC region.

Seed-2-Table brings together emerging life sciences companies to present their technologies and capital strategies in an intimate, investor-focused setting designed to foster meaningful dialogue and long-term partnerships.

During the event, Pinco presented its non-viral DNA plasmid platform targeting Nav1.7, a genetically validated sodium channel implicated in neuropathic pain. The presentation highlighted:

• The significant unmet need in chronic neuropathic pain

• The scientific rationale for targeting Nav1.7

• Early in-vitro data demonstrating depletion of Nav1.7 expression

• A defined preclinical roadmap toward IND-enabling studies

• The company’s current pre-seed fundraising efforts

“Seed-2-Table provided an opportunity to engage directly with investors who understand the complexities of early-stage therapeutic development,” said Scott Alpizar, PhD, CEO of Pinco Biotherapeutics. “The focused format allowed for deeper discussions around our regulatory pathway, development milestones, and long-term licensing strategy.”

Pinco continues to advance its in-vitro optimization work while preparing for in-vivo validation studies as part of its broader development plan toward clinical translation.

About Pinco Biotherapeutics

Pinco Biotherapeutics is a preclinical therapeutics company developing non-viral DNA plasmid–based drugs for chronic neuropathic pain. By directly targeting validated molecular drivers of pain, Pinco’s plasmid is designed to deliver durable, non-addictive relief while avoiding the systemic side effects of small molecules and the immunogenicity risks of viral gene therapies.